EL7.AI
StocksMedium•29 July 2026•
1 min read

Krystal Biotech Hits Profitability on Strong VYJUVEK Sales

Key Facts

1Krystal Biotech generated $116.4M in VYJUVEK revenue during the first quarter.
2The company reported $56M in net income with a robust cash position of $1B.
3Upcoming catalysts include registrational data for KB803 and KB801 therapies.

In a move reflecting the successful commercialization of rare disease treatments, Krystal Biotech reported robust financial results for the first quarter. According to reports, the company generated $116.4M in revenue from its lead product, VYJUVEK, contributing to a net income of $56M. This performance underscores the firm's transition toward self-funding its research and development pipeline without relying on external capital.

The company currently maintains a robust cash position of $1B, supporting the continued growth of its HSV-1 platform. Per market dynamics, these results highlight the company's efficiency in converting scientific innovation into tangible commercial returns, specifically through the successful market penetration of VYJUVEK during the reported period.

Investors are now watching for upcoming catalysts, including registrational data for the KB803 and KB801 therapies. Initial Jobless Claims scheduled for release on July 23, 2026.